Tests ERAS-0015 alone or combined in advanced solid tumors
Tests whether ERAS-0015 is safe in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06983743, who can take part
Where in Canada
- The Princess Margaret Cancer CenterToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasca, Inc.
- Trial code
- NCT06983743EU 2026-525794-39-00
- Record updated
- 6 November 2026
- Original description
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.Read full original descriptionShow less
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Inclusion: Age ≥ 18 years; Willing and able to give written informed consent; Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts; There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy. Does not apply to newly diagnosed Pancreatic Ductal Carcinoma (PDAC) cohort; Able to swallow oral medication; Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1; Adequate cardiovascular, hematological, liver, and renal function; Willing to comply with all protocol-required visits, assessments, and procedures.
Exclusion: Previous treatment with a RAS inhibitor; Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-0015; Received prior palliative radiation within 14 days of Cycle 1, Day 1; Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption; Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs; Have primary central nervous system (CNS) tumors; Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial.